1.47
-0.01 (-0.68%)
| Penutupan Terdahulu | 1.48 |
| Buka | 1.48 |
| Jumlah Dagangan | 2,627,130 |
| Purata Dagangan (3B) | 3,875,596 |
| Modal Pasaran | 989,016,000 |
| Harga / Jualan (P/S) | 1.45 |
| Harga / Buku (P/B) | 0.710 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 25 Feb 2025 - 3 Mar 2025 |
| Margin Keuntungan | -18.80% |
| Margin Operasi (TTM) | -61.78% |
| EPS Cair (TTM) | -0.190 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | -2.80% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 36.51% |
| Nisbah Semasa (MRQ) | 2.97 |
| Aliran Tunai Operasi (OCF TTM) | -177.37 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -110.04 M |
| Pulangan Atas Aset (ROA TTM) | -8.97% |
| Pulangan Atas Ekuiti (ROE TTM) | -9.39% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Diagnostics & Research (US) | Bercampur | Bercampur |
| Diagnostics & Research (Global) | Bercampur | Bercampur | |
| Stok | Opko Health, Inc. | Menurun | Menurun |
AISkor Stockmoo
| Konsensus Penganalisis | -0.5 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -1.0 |
| Purata Bergerak Teknikal | -2.5 |
| Osilator Teknikal | -0.5 |
| Purata | -1.13 |
|
OPKO Health Inc is a diversified biotechnology company that operates pharmaceutical and diagnostic development programs. Opko's diagnostics business includes a core genetic testing operation. It has a development and commercial supply pharmaceutical company, as well as a world supply-chain operation and holding company in Ireland. It also owns a specialty active pharmaceutical ingredients manufacturer in Israel. It operates in two segments Diagnostics and Pharmaceuticals. |
|
| Sektor | Healthcare |
| Industri | Diagnostics & Research |
| Gaya Pelaburan | Small Value |
| % Dimiliki oleh Orang Dalam | 54.47% |
| % Dimiliki oleh Institusi | 28.02% |
| Julat 52 Minggu | ||
| Median | 2.25 (53.06%) | |
| Jumlah | 1 Beli | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| Barrington Research | 08 Nov 2024 | 2.25 (53.06%) | Beli | 1.52 |
Tiada data dalam julat masa ini.
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2025 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |